Change in baseline trough FEV1 · stable COPD
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… probably leads to higher trough FEV1 change from baseline compared with LABA plus inhaled corticosteroid (ICS) (moderate certainty).
1 finding from 1 review
Pneumonia · stable COPD
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… leads to lower pneumonia compared with LABA plus inhaled corticosteroid (ICS) (high certainty).
1 finding from 1 review
All‐cause death · stable COPD
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… probably leads to higher all‐cause death compared with LABA plus inhaled corticosteroid (ICS) (moderate certainty).
1 finding from 1 review
SGRQ total score change from baseline (≥ 4 points, MCID) · stable COPD
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… showed no clear difference in SGRQ total score change from baseline (≥ 4 points, MCID) compared with LABA plus inhaled corticosteroid (ICS) (moderate certainty).
1 finding from 1 review
BPD at 28 days · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes BPD defined as an oxygen requirement at 28 days№ of participants:… compared with placebo (very low certainty).
1 finding from 1 review
RR 1.09 [0.94, 1.26]
Studies not reported
Very low
Bronchopulmonary dysplasia · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes BPD defined as oxygen at 36 weeks' postmenstrual age№ of… compared with placebo (very low certainty).
1 finding from 1 review
RR 0.96 [0.72, 1.29]
Studies not reported
Very low
Neonatal mortality · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes neonatal mortality (i.e. within 28 days)№ of participants: 335(2 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
RR 0.98 [0.57, 1.68]
Studies not reported
Very low
Mortality before hospital discharge · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes mortality prior to discharge№ of participants: 78(2 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
RR 1.2 [0.53, 2.71]
Studies not reported
Very low
BPD or death at 36 weeks' postmenstrual age№ of participants: 0 (0 RCTs) · preterm infants at risk for bronchopulmonary dysplasia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for supplemental oxygen (days)№ of participants: 0 (0 RCTs) · preterm infants at risk for bronchopulmonary dysplasia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Retinopathy of prematurity · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes retinopathy of prematurity№ of participants: 277(2 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
RR 0.95 [0.78, 1.15]
Studies not reported
Very low
Severe retinopathy of prematurity (stage II or greater)№ of participants: 244(1 RCT) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes severe retinopathy of prematurity (stage II or greater)№ of… compared with placebo (very low certainty).
1 finding from 1 review
RR 0.97 [0.57, 1.65]
Studies not reported
Very low
Moderate to severe neurodevelopmental outcome at 18 to 24 months№ of participants: 0 (0 RCTs) · preterm infants at risk for bronchopulmonary dysplasia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Clinical HINTS
1 finding from 1 review
Intervention not reported
Investigation of heterogeneity and sensitivity analyses
1 finding from 1 review
no estimate extracted
95 participants
Moderate
Intervention not reported
Conclusions
1 finding from 1 review
no estimate extracted
94 participants
GRADE not reported
Intervention not reported
Video‐assisted HINTS
1 finding from 1 review
Intervention not reported
Clinical HINTS Plus
1 finding from 1 review
Intervention not reported
Video‐assisted HINTS Plus
1 finding from 1 review
Intervention not reported
Secondary objectives for HINTS subcomponents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found